Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497363 | 0.87 | POLB (0.49) | HPGDPOLBKMT2AMEN1MAPT | |
| SCHEMBL31539476 | 0.87 | POLB (0.49) | HPGDPOLBKMT2AMEN1MAPT | |
| SCHEMBL11696347 | 0.86 | POLB (0.68) | HPGDPOLBKMT2AMEN1MAPT | |
| SCHEMBL6772611 | 0.85 | HPGD (0.64) | HPGDKMT2AMEN1MAPTGAA | |
| SCHEMBL16456324 | 0.82 | HPGD (0.74) | HPGDKMT2AMEN1MAPTRAB9A | |
| SCHEMBL1144467 | 0.82 | HPGD (0.67) | HPGDPOLBKMT2AMEN1MAPT | |
| SCHEMBL11839926 | 0.82 | KMT2A (0.73) | HPGDPOLBKMT2AMEN1MAPT | |
| SCHEMBL1144626 | 0.82 | HPGD (0.71) | HPGDPOLBKMT2AMEN1MAPT | |
| SCHEMBL31422646 | 0.81 | HPGD (1.00) | HPGDKMT2AMEN1GAAALDH1A1 | |
| SCHEMBL143970 | 0.81 | HPGD (1.00) | HPGDKMT2AMEN1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677368-B2 | 4-aryl substituted indolinones | SUGEN, INC. | 2004-01-13 | — | — | US | claimed |
| US-20030069297-A1 | 4-aryl substituted indolinones | SUGEN, INC. | 2003-04-10 | — | — | US | claimed |
| US-6861418-B2 | 4-aryl substituted indolinones | SUGEN, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
| US-4977178-A | Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents | PFIZER INC. (US) | 1990-12-11 | — | — | US | disclosed |
| US-4879391-A | 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents | PFIZER INC. (US) | 1989-11-07 | — | — | US | disclosed |
| US-4861880-A | 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents | PFIZER INC. (US) | 1989-08-29 | — | — | US | disclosed |
| EP-0104860-B1 | 1-PHENYL-2(1H,3H)-INDOLONE PSYCHO-THERAPEUTIC AGENTS | PFIZER INC. (US) | 1987-03-18 | — | — | EP | disclosed |
| US-4476307-A | Heteroylidene indolone compounds | PFIZER INC. (US) | 1984-10-09 | — | — | US | disclosed |
| EP-0104860-A1 | 1-Phenyl-2(1H,3H)-indolone psycho-therapeutic agents | PFIZER INC. (US) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069297-A1 | 4-aryl substituted indolinones | CDK5, CAMK4, TNK2 | HPGD 1764/4885POLB 3557/4885KMT2A 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.